Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Receives Average Rating of “Buy” from Analysts

Shares of Taysha Gene Therapies, Inc. (NASDAQ:TSHA) have received an average rating of “Buy” from the eight brokerages that are covering the company, MarketBeat Ratings reports. Eight investment analysts have rated the stock with a buy rating. The average 12-month price target among brokers that have covered the stock in the last year is $6.38.

A number of brokerages recently issued reports on TSHA. Needham & Company LLC dropped their target price on shares of Taysha Gene Therapies from $7.00 to $6.00 and set a “buy” rating on the stock in a research report on Monday, August 12th. Canaccord Genuity Group dropped their target price on shares of Taysha Gene Therapies from $7.00 to $6.00 and set a “buy” rating on the stock in a research report on Wednesday, August 14th. Finally, Chardan Capital reaffirmed a “buy” rating and set a $7.00 target price on shares of Taysha Gene Therapies in a research report on Tuesday, August 13th.

Institutional Investors Weigh In On Taysha Gene Therapies

Several institutional investors and hedge funds have recently bought and sold shares of the business. Avoro Capital Advisors LLC increased its holdings in Taysha Gene Therapies by 328.2% in the 1st quarter. Avoro Capital Advisors LLC now owns 18,650,000 shares of the company’s stock valued at $53,526,000 after buying an additional 14,294,445 shares during the period. Artal Group S.A. boosted its stake in shares of Taysha Gene Therapies by 0.7% in the 1st quarter. Artal Group S.A. now owns 3,687,548 shares of the company’s stock valued at $10,583,000 after purchasing an additional 24,444 shares in the last quarter. StemPoint Capital LP acquired a new stake in shares of Taysha Gene Therapies in the 1st quarter valued at $3,122,000. Quantum Private Wealth LLC boosted its stake in shares of Taysha Gene Therapies by 5.1% in the 3rd quarter. Quantum Private Wealth LLC now owns 767,616 shares of the company’s stock valued at $1,543,000 after purchasing an additional 37,096 shares in the last quarter. Finally, Bank of New York Mellon Corp acquired a new stake in shares of Taysha Gene Therapies in the 2nd quarter valued at $1,018,000. Institutional investors own 77.70% of the company’s stock.

Taysha Gene Therapies Trading Down 5.2 %

NASDAQ:TSHA opened at $1.27 on Wednesday. Taysha Gene Therapies has a 12 month low of $1.19 and a 12 month high of $4.32. The firm has a market cap of $260.27 million, a price-to-earnings ratio of -6.35 and a beta of 0.44. The company has a quick ratio of 5.22, a current ratio of 5.22 and a debt-to-equity ratio of 0.35. The company’s 50 day moving average is $2.04 and its 200-day moving average is $2.42.

Taysha Gene Therapies (NASDAQ:TSHA) last released its quarterly earnings results on Monday, August 12th. The company reported ($0.09) EPS for the quarter, beating analysts’ consensus estimates of ($0.10) by $0.01. Taysha Gene Therapies had a negative net margin of 888.18% and a negative return on equity of 168.91%. The company had revenue of $1.11 million for the quarter, compared to analyst estimates of $3.62 million. During the same quarter last year, the firm posted ($0.38) earnings per share. Equities analysts anticipate that Taysha Gene Therapies will post -0.35 EPS for the current year.

About Taysha Gene Therapies

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.